{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:33:23Z","timestamp":1793658803918,"version":"4.5.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The central role played by cerebrospinal-fluid (CSF) examinations including antineuronal autoantibody (Ab) testing is increasingly recognized in psychiatry. The rationale of this study was to present a multimodally investigated group of patients. In total, 992 patients were analyzed for CSF alterations: 456 patients with schizophreniform and 536 with affective syndromes. Ab measurement included testing for established antineuronal IgG-Abs against intracellular antigens in serum (Yo\/Hu\/Ri\/cv2[CRMP5]\/Ma1\/Ma2\/SOX1\/TR[DNER]\/Zic4\/amphiphysin\/GAD65) and for cell surface antigens in the CSF (NMDAR\/AMPA-1\/2-R\/GABA-B-R\/LGI1\/CASPR2\/DPPX). In 30 patients with \u201cred flags\u201d for autoimmune psychosis, \u201ctissue tests\u201d were performed. Additional diagnostics included MRI and EEG analyses. CSF white-blood-cell counts were increased in 4% and IgG indices in 2%; CSF-specific oligoclonal bands were detected in 4%; overall, 8% displayed signs of neuroinflammation. In addition, 18% revealed increased albumin quotients. Antineuronal Abs against intracellular antigens were detected in serum in 0.6%. Antineuronal Abs against established cell surface antigens were detected in serum of 1% and in the CSF of 0.3% (CSF samples were only questionably positive). Abnormal IgG binding in \u201ctissue tests\u201d was detected in serum of 23% and in CSF of 27%. In total, 92% of the Ab-positive patients demonstrated at least one sign of brain involvement in additional diagnostics using CSF, MRI, EEG, and FDG-PET. In summary, CSF basic analyses revealed signs of blood\u2013brain-barrier dysfunction and neuroinflammation in relevant subgroups of patients. Established antineuronal IgG-Abs were rare in serum and even rarer in the CSF. \u201cTissue tests\u201d revealed frequent occurrences of Ab-binding; therefore, novel antineuronal Abs could play a relevant role in psychiatry.<\/jats:p>","DOI":"10.1038\/s41398-020-00967-3","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T03:56:28Z","timestamp":1597204588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7322-1195","authenticated-orcid":false,"given":"Dominique","family":"Endres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Meixensberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Dersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-1258","authenticated-orcid":false,"given":"Bernd","family":"Feige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Stich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Venhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Matysik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimon","family":"Runge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Urbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Domschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-7976","authenticated-orcid":false,"given":"Harald","family":"Pr\u00fcss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Tebartz van Elst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"967_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 15, 391\u2013404 (2016).","journal-title":"Lancet Neurol."},{"key":"967_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2215-0366(19)30290-1","volume":"7","author":"TA Pollak","year":"2020","unstructured":"Pollak, T. A. et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry 7, 93\u2013108 (2020).","journal-title":"Lancet Psychiatry"},{"key":"967_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00115-014-4030-x","volume":"85","author":"O Stich","year":"2014","unstructured":"Stich, O. & Rauer, S. [Paraneoplastic neurological syndromes and autoimmune encephalitis]. Nervenarzt 85, 485\u2013498 (2014). quiz 499-501.","journal-title":"Nervenarzt"},{"key":"967_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","volume":"18","author":"J Dalmau","year":"2019","unstructured":"Dalmau, J. et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 18, 1045\u20131057 (2019).","journal-title":"Lancet Neurol."},{"key":"967_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","volume":"7","author":"J Dalmau","year":"2008","unstructured":"Dalmau, J. et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 7, 1091\u20131098 (2008).","journal-title":"Lancet Neurol."},{"key":"967_CR6","doi-asserted-by":"crossref","unstructured":"Endres, D. et al. [Autoantibody-associated schizophreniform psychoses: clinical symptomatology]. Nervenarzt. 90, 547\u2013563 (2019).","DOI":"10.1007\/s00115-019-0700-z"},{"key":"967_CR7","doi-asserted-by":"crossref","unstructured":"Tebartz van Elst, L. et al. [Autoantibody-associated schizophreniform psychoses: pathophysiology, diagnostics, and treatment]. Nervenarzt. 90, 745\u2013761 (2019).","DOI":"10.1007\/s00115-019-0735-1"},{"key":"967_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","volume":"378","author":"J Dalmau","year":"2018","unstructured":"Dalmau, J. & Graus, F. Antibody-mediated encephalitis. N. Engl. J. Med. 378, 840\u2013851, https:\/\/doi.org\/10.1056\/NEJMra1708712 (2018).","journal-title":"N. Engl. J. Med."},{"key":"967_CR9","doi-asserted-by":"crossref","unstructured":"Endres D., et al. Probable autoimmune catatonia with antibodies against cilia on hippocampal granule cells and highly suspicious cerebral FDG-PET findings. Biol. Psychiatry. 87, e29\u2013e31 (2020).","DOI":"10.1016\/j.biopsych.2019.12.020"},{"key":"967_CR10","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/brain\/aww208","volume":"139","author":"J Kreye","year":"2016","unstructured":"Kreye, J. et al. Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain 139, 2641\u20132652 (2016).","journal-title":"Brain"},{"key":"967_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ana.24189","volume":"76","author":"L Dahm","year":"2014","unstructured":"Dahm, L. et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann. Neurol. 76, 82\u201394 (2014).","journal-title":"Ann. Neurol."},{"key":"967_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/mp.2013.110","volume":"19","author":"C Hammer","year":"2014","unstructured":"Hammer, C. et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol. Psychiatry 19, 1143\u20131149 (2014).","journal-title":"Mol. Psychiatry"},{"key":"967_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2215-0366(16)30375-3","volume":"4","author":"BR Lennox","year":"2017","unstructured":"Lennox, B. R. et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry 4, 42\u201348 (2017).","journal-title":"Lancet Psychiatry"},{"key":"967_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3389\/fnhum.2015.00476","volume":"9","author":"D Endres","year":"2015","unstructured":"Endres, D. et al. Immunological findings in psychotic syndromes: a tertiary care hospital\u2019s CSF sample of 180 patients. Front Hum. Neurosci. 9, 476 (2015).","journal-title":"Front Hum. Neurosci."},{"key":"967_CR15","doi-asserted-by":"crossref","unstructured":"Oviedo-Salcedo, T. et al. Absence of cerebrospinal fluid antineuronal antibodies in schizophrenia spectrum disorders. Br. J. Psychiatry. 212, 318\u2013320 (2018).","DOI":"10.1192\/bjp.2018.24"},{"key":"967_CR16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3389\/fneur.2019.00804","volume":"10","author":"T Blinder","year":"2019","unstructured":"Blinder, T. & Lewerenz, J. Cerebrospinal fluid findings in patients with autoimmune encephalitis\u2014a systematic analysis. Front Neurol. 10, 804 (2019).","journal-title":"Front Neurol."},{"key":"967_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-015-0552-4","volume":"15","author":"D Endres","year":"2015","unstructured":"Endres, D. et al. Hypoglutamatergic state is associated with reduced cerebral glucose metabolism in anti-NMDA receptor encephalitis: a case report. BMC Psychiatry 15, 186 (2015).","journal-title":"BMC Psychiatry"},{"key":"967_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.4088\/JCP.10l06510","volume":"72","author":"LT van Elst","year":"2011","unstructured":"van Elst, L. T., Kl\u00f6ppel, S. & Rauer, S. Voltage-gated potassium channel\/LGI1 antibody-associated encephalopathy may cause brief psychotic disorder. J. Clin. Psychiatry 72, 722\u2013723 (2011).","journal-title":"J. Clin. Psychiatry"},{"key":"967_CR19","unstructured":"Rush, A. J. Handbook of Psychiatric Measures, 1st ed. American Psychiatric Association, Washington, DC (2000)."},{"key":"967_CR20","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed. Arlington, VA (2009)."},{"key":"967_CR21","unstructured":"Arbeitsgemeinschaft f\u00fcr Methodik und Dokumentation in der Psychiatrie. Das AMDP-System: Manual zur Dokumentation psychiatrischer Befunde. 10th ed. Hogrefe, G\u00f6ttingen (2018)."},{"key":"967_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","volume":"8","author":"S Engelborghs","year":"2017","unstructured":"Engelborghs, S. et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst.). 8, 111\u2013126 (2017).","journal-title":"Alzheimers Dement (Amst.)."},{"key":"967_CR23","first-page":"194","volume":"7","author":"D Endres","year":"2016","unstructured":"Endres, D. et al. Alterations in cerebrospinal fluid in patients with bipolar syndromes. Front Psychiatry 7, 194 (2016).","journal-title":"Front Psychiatry"},{"key":"967_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jad.2016.03.030","volume":"198","author":"D Endres","year":"2016","unstructured":"Endres, D. et al. Evidence of cerebrospinal fluid abnormalities in patients with depressive syndromes. J. Affect Disord. 198, 178\u2013184 (2016).","journal-title":"J. Affect Disord."},{"key":"967_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1007\/s00415-018-8779-x","volume":"265","author":"T Hottenrott","year":"2018","unstructured":"Hottenrott, T. et al. The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis. J. Neurol. 265, 1106\u20131114 (2018).","journal-title":"J. Neurol."},{"key":"967_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bdi.12244","volume":"17","author":"O Stich","year":"2015","unstructured":"Stich, O. et al. An observational study of inflammation in the central nervous system in patients with bipolar disorder. Bipolar Disord. 17, 291\u2013302 (2015).","journal-title":"Bipolar Disord."},{"key":"967_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fpsyt.2017.00025","volume":"8","author":"J Herken","year":"2017","unstructured":"Herken, J. & Pr\u00fcss, H. Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front Psychiatry 8, 25 (2017).","journal-title":"Front Psychiatry"},{"key":"967_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000569","volume":"6","author":"H Schumacher","year":"2019","unstructured":"Schumacher, H. et al. IgA autoantibodies against native myelin basic protein in a patient with MS. Neurol. Neuroimmunol. Neuroinflamm. 6, e569 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"967_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.yebeh.2017.06.039","volume":"75","author":"D Endres","year":"2017","unstructured":"Endres, D. et al. Increased rates of intermittent rhythmic delta and theta activity in the electroencephalographies of adult patients with attention-deficit hyperactivity disorder. Epilepsy Behav. 75, 60\u201365 (2017).","journal-title":"Epilepsy Behav."},{"key":"967_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fnhum.2017.00066","volume":"11","author":"D Endres","year":"2017","unstructured":"Endres, D. et al. Altered intermittent rhythmic delta and theta activity in the electroencephalographies of high functioning adult patients with autism spectrum disorder. Front Hum. Neurosci. 11, 66 (2017).","journal-title":"Front Hum. Neurosci."},{"key":"967_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41380-018-0220-4","volume":"24","author":"S Orlovska-Waast","year":"2019","unstructured":"Orlovska-Waast, S. et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Mol. Psychiatry 24, 869\u2013887 (2019).","journal-title":"Mol. Psychiatry"},{"key":"967_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF00380949","volume":"236","author":"K Bauer","year":"1987","unstructured":"Bauer, K. & Kornhuber, J. Blood-cerebrospinal fluid barrier in schizophrenic patients. Eur. Arch. Psychiatry Neurol. Sci. 236, 257\u2013259 (1987).","journal-title":"Eur. Arch. Psychiatry Neurol. Sci."},{"key":"967_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/0006-3223(90)90401-M","volume":"28","author":"AF Pitts","year":"1990","unstructured":"Pitts, A. F., Carroll, B. T., Gehris, T. L., Kathol, R. G. & Samuelson, S. D. Elevated CSF protein in male patients with depression. Biol. Psychiatry 28, 629\u2013637 (1990).","journal-title":"Biol. Psychiatry"},{"key":"967_CR34","doi-asserted-by":"crossref","unstructured":"Zetterberg, H. et al. Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res. 217, 143\u2013146 (2014).","DOI":"10.1016\/j.psychres.2014.03.045"},{"key":"967_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fpsyt.2017.00083","volume":"8","author":"S Najjar","year":"2017","unstructured":"Najjar, S. et al. Neurovascular unit dysfunction and blood-brain barrier hyperpermeability contribute to schizophrenia neurobiology: a theoretical integration of clinical and experimental evidence. Front Psychiatry 8, 83 (2017).","journal-title":"Front Psychiatry"},{"key":"967_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fimmu.2017.00181","volume":"8","author":"H Ehrenreich","year":"2017","unstructured":"Ehrenreich, H. Autoantibodies against the N-methyl-d-aspartate receptor subunit NR1: untangling apparent inconsistencies for clinical practice. Front Immunol. 8, 181 (2017).","journal-title":"Front Immunol."},{"key":"967_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00406-011-0280-9","volume":"262","author":"N Vasic","year":"2012","unstructured":"Vasic, N., Connemann, B. J., Wolf, R. C., Tumani, H. & Brettschneider, J. Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand? Eur. Arch. Psychiatry Clin. Neurosci. 262, 375\u2013391 (2012).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"967_CR38","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3389\/fneur.2019.01086","volume":"10","author":"D Endres","year":"2019","unstructured":"Endres, D. et al. Psychiatric presentation of anti-NMDA receptor encephalitis. Front Neurol. 10, 1086 (2019).","journal-title":"Front Neurol."},{"key":"967_CR39","doi-asserted-by":"crossref","unstructured":"Endres D., et al. Probable autoimmune depression in a patient with multiple sclerosis and antineuronal antibodies. Front Psychiatry 11, 745 (2020).","DOI":"10.3389\/fpsyt.2020.00745"},{"key":"967_CR40","doi-asserted-by":"crossref","unstructured":"Endres D., et al. Novel antineuronal autoantibodies with somatodendritic staining pattern in a patient with autoimmune psychosis. Front Psychiatry 11, 627 (2020).","DOI":"10.3389\/fpsyt.2020.00627"},{"key":"967_CR41","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/acn3.50905","volume":"6","author":"F Shimizu","year":"2019","unstructured":"Shimizu, F. et al. GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica. Ann. Clin. Transl. Neurol. 6, 2079\u20132087 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"967_CR42","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1007\/s00115-018-0607-0","volume":"89","author":"S Jarius","year":"2018","unstructured":"Jarius, S. et al. [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing]. Nervenarzt 89, 1388\u20131399 (2018).","journal-title":"Nervenarzt"},{"key":"967_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-018-1929-z","volume":"13","author":"S Bejerot","year":"2019","unstructured":"Bejerot, S. et al. Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report. J. Med Case Rep. 13, 27 (2019).","journal-title":"J. Med Case Rep."},{"key":"967_CR44","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.biopsych.2014.09.011","volume":"78","author":"R Iorio","year":"2015","unstructured":"Iorio, R. Treatment-resistant depression and aquaporin-4 autoantibodies: is there a link? Biol. Psychiatry 78, e1\u2013e2 (2015).","journal-title":"Biol. Psychiatry"},{"key":"967_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","volume":"13","author":"N Gresa-Arribas","year":"2014","unstructured":"Gresa-Arribas, N. et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 13, 167\u2013177 (2014).","journal-title":"Lancet Neurol."},{"key":"967_CR46","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00415-005-0817-9","volume":"252","author":"J Brettschneider","year":"2005","unstructured":"Brettschneider, J., Claus, A., Kassubek, J. & Tumani, H. Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. J. Neurol. 252, 1067\u20131073 (2005).","journal-title":"J. Neurol."},{"key":"967_CR47","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.biopsych.2017.06.015","volume":"82","author":"J J\u00e9z\u00e9quel","year":"2017","unstructured":"J\u00e9z\u00e9quel, J. et al. Cell- and single molecule-based methods to detect anti-N-methyl-D-aspartate receptor autoantibodies in patients with first-episode psychosis from the OPTiMiSE project. Biol. Psychiatry 82, 766\u2013772 (2017).","journal-title":"Biol. Psychiatry"},{"key":"967_CR48","doi-asserted-by":"publisher","first-page":"e1386","DOI":"10.1212\/WNL.0000000000005329","volume":"90","author":"M Hara","year":"2018","unstructured":"Hara, M. et al. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology 90, e1386\u2013e1394 (2018).","journal-title":"Neurology"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00967-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00967-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:32:13Z","timestamp":1670250733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-00967-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1038\/s41398-020-00967-3","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"25 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original HTML version of this Article was updated shortly after publication to add the Projekt DEAL funding acknowledgement.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.E.: None. S.M.: None. B.F.: None. R.D.: Lecture fees from Roche and travel grants from Biogen. O.S.: None. N.V.: Advisory boards, lectures, and travel grants from Roche. S.M.: None. M.Ma.: None. M.Mi.: None. K.R.: None. K.N.: None. H.U.: Shareholder of the Veobrain: K.D.: Steering Committee Neurosciences, Janssen. H.P.: None. L.T.v.E.: Advisory boards, lectures, or travel grants within the last three years: Roche, Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen, and Cyberonics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"279"}}